001     119413
005     20240228134939.0
024 7 _ |a 10.4161/cbt.29503
|2 doi
024 7 _ |a pmid:24918923
|2 pmid
024 7 _ |a pmc:PMC4128861
|2 pmc
024 7 _ |a 1538-4047
|2 ISSN
024 7 _ |a 1538-4077
|2 ISSN
024 7 _ |a 1555-8576
|2 ISSN
024 7 _ |a altmetric:2535714
|2 altmetric
037 _ _ |a DKFZ-2017-00155
041 _ _ |a eng
082 _ _ |a 570
100 1 _ |a Adwan, Hassan
|0 P:(DE-HGF)0
|b 0
|e First author
245 _ _ |a Riproximin's activity depends on gene expression and sensitizes PDAC cells to TRAIL.G401
260 _ _ |a Georgetown, Tex.
|c 2014
|b Landes Bioscience
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1487772058_1763
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Riproximin (Rpx) is a type II ribosome inactivating protein, which was investigated for its activity in pancreatic ductal adenocarcinoma (PDAC) in a panel of 17 human and rat PDAC cell lines and in rat pancreatic cancer liver metastasis. Cytotoxicity in response to Rpx was determined by MTT assay, apoptosis by flow cytometry and qRT-PCR for apoptosis related genes, and the modulation of the transcriptome was monitored by micro array analysis. The combination effect of Rpx and TRAIL was assessed by MTT assay. Rpx showed high but varying cytotoxicity in PDAC cells. Based on overall gene expression, the sensitivity of these cells was linked to genes involved in apoptosis. Furthermore, based on the affinity of Rpx for CEA, the expression of carcinoembryonic antigen-related cell adhesion molecule (CEACAM) genes was significantly related to Rpx's cytotoxicity in cells with CEACAM gene expression. Exposure of Suit2-007 cells to Rpx induced the mRNA expression of members of signaling pathways initiating from most death receptors, and down modulation of TRAIL. Apoptosis was increased as shown by FACS analysis. Combination of Rpx with TRAIL resulted in a synergistic cytotoxic effect in human Suit2-007 and rat ASML cells, as evidenced by a 6-fold lower tumor cell survival than expected from an additive combination effect. Treatment of BDX rats bearing intra-portally implanted Suit2-007 cells showed a highly significant anticancer effect and indicated an application of Rpx against pancreatic cancer metastasis to the liver. These data favor further evaluation of Rpx as anticancer agent in PDAC.
536 _ _ |a 317 - Translational cancer research (POF3-317)
|0 G:(DE-HGF)POF3-317
|c POF3-317
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Antineoplastic Agents
|2 NLM Chemicals
650 _ 7 |a Apoptosis Regulatory Proteins
|2 NLM Chemicals
650 _ 7 |a Plant Proteins
|2 NLM Chemicals
650 _ 7 |a TNF-Related Apoptosis-Inducing Ligand
|2 NLM Chemicals
650 _ 7 |a riproximin protein, Ximenia americana
|2 NLM Chemicals
700 1 _ |a Murtaja, Ahmed
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Kadhim Al-Taee, Khamael
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Pervaiz, Asim
|0 P:(DE-He78)17064a887f14c1cee3ae16af3cf73314
|b 3
|u dkfz
700 1 _ |a Hielscher, Thomas
|0 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f
|b 4
|u dkfz
700 1 _ |a Berger, Martin
|0 P:(DE-He78)7e60033e3eaaebb9ba30c905ade4a676
|b 5
|e Last author
|u dkfz
773 _ _ |a 10.4161/cbt.29503
|g Vol. 15, no. 9, p. 1185 - 1197
|0 PERI:(DE-600)2088895-8
|n 9
|p 1185 - 1197
|t Cancer biology & therapy
|v 15
|y 2014
|x 1555-8576
909 C O |o oai:inrepo02.dkfz.de:119413
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)17064a887f14c1cee3ae16af3cf73314
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)7e60033e3eaaebb9ba30c905ade4a676
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-317
|2 G:(DE-HGF)POF3-300
|v Translational cancer research
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2014
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCER BIOL THER : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-He78)G401-20160331
|k G401
|l Toxikologie und Chemotherapie
|x 0
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l Biostatistik
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)G401-20160331
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21